Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Evommune, Inc. (EVMN)

Evommune to host EVO570 webcast on licensed VAV1 degrader from Hinova Pharmaceuticals

Neutral Impact 2 of 5 product/contract Written later

Evommune announced a pre-recorded webcast at 8:30 a.m. ET on November 5, 2026, where CEO Luis Peña and management will discuss EVO570, an oral VAV1-directed molecular glue degrader the company in-licensed from Hinova Pharmaceuticals. The filing contains no new financial results or deal terms, but it signals management's focus on the transaction and the planned rheumatoid arthritis development path.

Key points

  • Pre-recorded webcast available at 8:30 a.m. ET on Thursday, November 5, 2026, with an archived replay for 30 days
  • Exclusive license from Hinova Pharmaceuticals (SSE: 688302) grants worldwide rights to EVO570 outside Greater China
  • Webcast will not include a live question-and-answer session; questions can go to investor relations
  • EVO570 is an investigational drug candidate and has not been approved by any regulatory authority

The filing

CompanyEvommune, Inc. (EVMN)
Form8-K, current report
Filed with the SECNov 5, 2026, 6:32 AM ET
Accession number0001193125-26-448443

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.